Björn S.
- Country
- Germany
- Department
- Medizinische Klinik II, Hämatologie/Onkologie/Infektologie
Research Overview
- Efficacy of Venetoclax and Azacitidine Versus Standard Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with NPM1 Mutations
- Phase I/II Study of Venetoclax, Cytarabine, and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia Eligible for Intensive Salvage Therapy
- Evaluation of Midostaurin and Gemtuzumab Ozogamicin in Combination with Standard Induction Chemotherapy for Adult Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 21 of 148 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on developing innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- First-line Treatment Strategies
- Refractory Disease Management
- Post-transplant Recurrence
The research encompasses treatment options for patients eligible for intensive therapy protocols.
Novel Therapeutic Combinations
The investigator explores innovative drug combinations incorporating targeted therapies and established treatments including venetoclax, azacitidine, and cytarabine-based regimens.
- Targeted Molecular Therapies
- Combination Treatment Approaches
- Dose Optimization Studies
Their work focuses on developing optimized treatment protocols for various AML patient populations.
Personalized Medicine
The investigator's research includes treatment strategies for specific patient subgroups, including those with NPM1 mutations and various genetic profiles in AML.
- Molecular-based Treatment Selection
- Patient-specific Approaches
- Treatment Response Assessment
Their work emphasizes individualized treatment strategies based on molecular and genetic characteristics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.